Skip to main content

Advertisement

Springer Nature Link
Log in

Relationship between IL-10 expression and prognosis in patients with primary breast cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

This retrospective study was designed to investigate the relationship between the expression of IL-10, CD4, CD8, and FOXP3 and clinicopathological features and prognosis in breast cancer patients. The expression of IL-10, CD4, CD8, and FOXP3 was detected by immunohistochemistry. Staining intensity of only IL-10 was associated with disease-free survival and distance disease-free survival (P < 0.05). Staining density of IL-10 in stromal cells was associated with overall survival and distance disease-free survival (P < 0.05). IL-10 expression levels might be used as a prognostic indicator for the recurrence, metastasis, and survival of breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33:S79–84.

    Article  PubMed  Google Scholar 

  2. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res. 1999;5:189–96.

    CAS  PubMed  Google Scholar 

  3. Nishimura Y, Taguchi M, Nagai T, Fujihara M, Honda S, Uenishi M. Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size. Clin Ophthalmol. 2012;6:365–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Chu D, Lu J. Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol. 2008;1:16.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 2010;29:569–79.

    Article  CAS  PubMed  Google Scholar 

  6. Hamidullah A, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 2012;133:11–21.

    Article  CAS  PubMed  Google Scholar 

  7. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–102.

    Article  PubMed  Google Scholar 

  8. Kundu N, Dorsey R, Jackson MJ, Guiterrez P, Wilson K, Fu S, et al. Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer. 1998;76:713–9.

    Article  CAS  PubMed  Google Scholar 

  9. Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21:331–44.

    Article  CAS  PubMed  Google Scholar 

  10. Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, et al. IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res. 2013;19:4092–103.

    Article  CAS  PubMed  Google Scholar 

  11. Zechmeister-Koss I, Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macularoedema: a systematic review. Br J Ophthalmol. 2012;96:167–78.

    Article  PubMed  Google Scholar 

  12. Rao VS, Alabi A, Dyer CE, Greenman J, Drew PJ. IL-10 and IL-12 expression in breast cancer patients and effect of therapy—ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol. 2008;26:14016.

    Google Scholar 

  13. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007;9:R15.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Núñez G, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res. 2012;72:420–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Kozowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82–4.

    Google Scholar 

  16. Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes. 2012;5:110.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 2009;29:2445–51.

    CAS  PubMed  Google Scholar 

  18. Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes. 2012;5:11.

    Article  Google Scholar 

  19. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949–55.

    Article  PubMed  Google Scholar 

  20. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14:R48.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflicts of interest

The authors report no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China

    Ying Li, Ping Gao, Junlan Yang, Haiming Yu, Yanyun Zhu & Wen Si

Authors
  1. Ying Li
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Ping Gao
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Junlan Yang
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Haiming Yu
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Yanyun Zhu
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Wen Si
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Junlan Yang.

Additional information

Ying Li and Ping Gao contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Gao, P., Yang, J. et al. Relationship between IL-10 expression and prognosis in patients with primary breast cancer. Tumor Biol. 35, 11533–11540 (2014). https://doi.org/10.1007/s13277-014-2249-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2249-6

Keywords